Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons

Neurobiology of Aging
P ReyJose L Labandeira-Garcia

Abstract

Angiotensin II activates (via type 1 receptors) NAD(P)H-dependent oxidases, which are a major source of superoxide, and is relevant in the pathogenesis of several cardiovascular diseases and certain degenerative changes associated with ageing. Given that there is a brain renin-angiotensin system and that oxidative stress is a key contributor to Parkinson's disease, we investigated the effects of angiotensin II and angiotensin type 1 (AT(1)) receptor antagonists in the 6-hydroxydopamine model of Parkinson's disease. Rats subjected to intraventricular injection of 6-hydroxydopamine showed bilateral reduction in the number of dopaminergic neurons and terminals. Injection of angiotensin alone did not induce any significant effect. However, angiotensin increased the toxic effect of 6-hydroxydopamine. Rats treated with the AT(1) receptor antagonist ZD 7155 and then 6-hydroxydopamine (with or without exogenous administration of angiotensin) showed a significant reduction in 6-hydroxydopamine-induced oxidative stress (lipid peroxidation and protein oxidation) and dopaminergic degeneration. Dopaminergic degeneration was also reduced by the NAD(P)H inhibitor apocynin. Angiotensin may play a pivotal role, via AT(1) receptors, in increasin...Continue Reading

References

Jan 1, 1990·Neuroscience·A D IntebiC F Deschepper
Dec 9, 1988·Science·R L StornettaK R Lynch
May 1, 1988·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·H J GundersenA Vesterby
Aug 1, 1995·Clinical and Experimental Hypertension : CHE·C J LebrunT Unger
Aug 26, 1998·Biochimica Et Biophysica Acta·G Lenaz
Oct 10, 1998·Brain Research Bulletin·A M AllenF A Mendelsohn
Oct 13, 2000·British Journal of Pharmacology·H Y SohnU Pohl
Sep 26, 2001·Circulation·T Münzel, J F Keaney
Apr 24, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Elena M V de CavanaghCesar G Fraga
Dec 31, 2003·Biochemical and Biophysical Research Communications·M Devrim DoganNihal Tümer
May 7, 2004·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Min LouJuraj Culman
May 19, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Ikuyo KusakaJiping Tang
Jul 27, 2004·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·R M Touyz
Aug 18, 2004·Neurobiology of Aging·F L van MuiswinkelB Drukarch
Sep 10, 2004·The European Journal of Neuroscience·J Rodriguez-PallaresJ L Labandeira-Garcia
Apr 5, 2005·Brain Research·Myeung Ju KimDong Hoon Shin

❮ Previous
Next ❯

Citations

Dec 23, 2011·Brain : a Journal of Neurology·Ana I Rodriguez-PerezJose L Labandeira-Garcia
Aug 19, 2011·Molecular Neurodegeneration·Ana I Rodriguez-PerezJose L Labandeira-Garcia
Dec 6, 2012·Parkinson's Disease·John W Wright, Joseph W Harding
Jan 16, 2013·International Journal of Hypertension·Marie-Odile Guimond, Nicole Gallo-Payet
Dec 29, 2011·Frontiers in Bioscience (Elite Edition)·Agnes SimonyiGrace Y Sun
Oct 9, 2008·Neurochemical Research·C David Rollo
Jul 23, 2011·Progress in Neurobiology·John W Wright, Joseph W Harding
Jul 6, 2010·Respiratory Physiology & Neurobiology·Evelyn H Schlenker
Oct 14, 2010·Journal of Neuropathology and Experimental Neurology·Rita ValenzuelaJose L Labandeira-Garcia
May 24, 2008·Neurobiology of Disease·J Rodriguez-PallaresJ L Labandeira-Garcia
Mar 11, 2016·BMC Medical Genomics·Maykel Cruz-MonteagudoEduardo Tejera
Aug 9, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Jose L Labandeira-GarciaAna I Rodríguez-Perez
Nov 8, 2014·Glia·Ana I Rodriguez-PerezJose L Labandeira-Garcia
Oct 2, 2015·Aging and Disease·Claudia Rangel-BarajasBenjamín Florán
Sep 29, 2007·Biochemical and Biophysical Research Communications·Tom N GrammatopoulosDavid G Standaert
Jun 19, 2013·Neurobiology of Disease·Ana I Rodriguez-PerezJose L Labandeira-Garcia
Nov 30, 2014·Neurobiology of Aging·Ana I Rodriguez-PerezJose L Labandeira-Garcia
Feb 18, 2014·Neurobiology of Aging·Begoña Villar-ChedaJose L Labandeira-Garcia
Jun 29, 2010·Experimental Neurology·Ana I Rodriguez-PerezJose L Labandeira-Garcia
Dec 3, 2014·Progress in Neurobiology·John W WrightJoseph W Harding
Nov 5, 2013·Experimental Neurology·Pablo Garrido-GilJose L Labandeira-Garcia
Oct 31, 2013·The International Journal of Neuropsychopharmacology·Ramiro Gonzalez-AparicioFernando Rodriguez de Fonseca
Jul 30, 2014·Frontiers in Neuroanatomy·Jose L Labandeira-GarcíaAna I Rodríguez-Perez
Aug 20, 2016·Journal of the Neurological Sciences·Natalia Pessoa RochaAntônio Lúcio Teixeira
Oct 18, 2014·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Jose L Labandeira-GarciaMaria J Guerra
Feb 22, 2018·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Linhong JiangXiaobo Cen
Oct 29, 2009·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Birgit MertensSophie Sarre
Jan 10, 2018·Frontiers in Aging Neuroscience·Sandra ZárateRicardo Gredilla
Feb 7, 2018·Molecular Neurobiology·Pablo Garrido-GilJose L Labandeira-Garcia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Aging-Associated Metabolic Disorders

Age is associated with many metabolic disorders including cardiovascular diseases, type 2 diabetes, stroke and heart disease. The mediators in aging process have been suggested to play a part in the cellular processes responsible for these metabolic disorders. Here is the latest research on aging-associated metabolic disorders.